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Abstract
Background: Oral sodium phosphate solutions (OSPS) are widely used for bowel cleansing prior to colonoscopy and other
procedures. Cases of renal failure due to acute phosphate nephropathy following OSPS ingestion have been documented in
recent years, questioning the safety of OSPS. However, the magnitude of the problem remains unknown.
Methodology/Principal Findings: We conducted a population based, retrospective analysis of medical records and biopsies
of all cases of acute phosphate nephropathy that were diagnosed in our country in the period from January 2005 to
October 2008. Utilizing the complete official sales figures of OSPS, we calculated the incidence of acute phosphate
nephropathy in our country. Fifteen cases of acute phosphate nephropathy were diagnosed per 17,651 sold doses of OSPS
(0.085%). Nine (60%) were women and mean age 69 years (range 56–75 years). Thirteen patients had a history of
hypertension (87%) all of whom were treated with either ACE-I or ARB and/or diuretics. One patient had underlying DM type
I and an active colitis and one patient had no risk factor for the development of acute phosphate nephropathy. Average
baseline creatinine was 81.7 mmol/L and 180.1 at the discovery of acute renal failure, mean 4.2 months after OSPS ingestion.
No patient had a full recovery of renal function, and at the end of follow-up, 26.6 months after the OSPS ingestion, the
average creatinine was 184.2 mmol/L. The average eGFR declined from 73.5 ml/min/1.73 m
2 at baseline to 37.3 ml/min/
1.73 m
2 at the end of follow-up. One patient reached end-stage renal disease and one patient died with progressive renal
failure.
Conclusion/Significance: Acute phosphate nephropathy developed in almost one out of thousand sold doses of OSPS. The
consequences for kidney function were detrimental. This information can be used in other populations to estimate the
impact of OSPS. Our data suggest that acute phosphate nephropathy may be greatly underreported worldwide.
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Introduction
Acute kidney injury (AKI) and subsequent chronic kidney disease
(CKD) have been reported after bowel cleansing with oral sodium
phosphate solutions (OSPS) [1]. The clinical pathological entity has
been termed ‘‘acute phosphate nephropathy’’ and is caused by
deposition of calcium phosphate crystals in the renal tubules,
resulting in acute tubular injury and eventual tubular atrophy and
interstitial fibrosis [2]. The first biopsy proven case report of this
toxic side effect on the kidneys was published in 2003 [3], 13 years
after sodium phosphate solutions began to be used as a purgative for
colonoscopy [4]. Subsequently, fewer than 40 cases of acute
phosphate nephropathy have been reported worldwide, with risk
factors of age (60+), female gender, hypertension, angiotensin
converting enzyme inhibitors (ACE-I), angiotensin receptor block-
ade (ARB), diuretics and chronic kidney disease [5–7]. During the
follow-up of patients with acute phosphate nephropathy, four
progressed to end-stage renal disease while the remaining patients
manifested chronic kidney disease [7]. Thus, while an association
between acute phosphate nephropathy and the ingestion of OSPS
has been well documented, there are no clear indications of the
global magnitude of this clinical problem. In fact, most clinicians
assume that acute phosphate nephropathy is a rare but serious side
effect of OSPS. In contrast, we hypothesize that the magnitude of
theproblemis highlyunderestimatedandinfact that themajorityof
cases remain unrecognized. Most cases of acute phosphate
nephropathy are clinically silent, and are often diagnosed by
chance many months after the ingestion of the OSPS. Furthermore,
elderly patients with an unexplained rise in creatinine without
urinary abnormalities are not likely to undergo a renal biopsy. As
OSPS has been a popular purgative for colonoscopy for almost 20
years in many countries it is possible that many individuals have
suffered unrecognized acute and subsequent chronic kidney injury
following ingestion of OSPS. A better knowledge of the incidence of
acutephosphate nephropathycould help toelucidate themagnitude
of this clinical problem.
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13484Here we present a population based, retrospective analysis of all
cases of acute phosphate nephropathy in Iceland. Furthermore, we
are able to provide the minimum incidence rate of acute
phosphate nephropathy in our country utilizing the complete
official sales figures of OSPS in Iceland.
Materials and Methods
This is a retrospective analysis of medical records and biopsies
of all cases of acute phosphate nephropathy that were diagnosed at
Landspitali University Hospital in Reykjavik, during the period
from January 2005 to October 2008. The study was approved by
the Icelandic Data Protection Authority, the Bioethics Committee
of Landspitali University Hospital and written consent was
obtained from all living participants.
Diagnostic criteria were, as proposed by Markowitz et al. [8], (1)
(acute) renal failure (2) pathologic findings of acute and/or chronic
tubular injury with abundant tubular calcium phosphate deposi-
tion and (3) exposure to oral sodium phosphate bowel cleansing
(Phosphoral (45 ml62), Laboratories Casen-Fleet S.L.U.). Index
cases were found by reviewing the pathological diagnosis of renal
biopsies performed in the study period. Medical records were
reviewed for age, gender, medical history, medication, the ingested
dose of OSPS, indication for colonoscopy and symptoms after
OSPS ingestion. The following serum creatinine values were
documented: at baseline, at presentation of kidney injury, at the
time of renal biopsy, the highest available, and the latest value.
Estimated glomerular filtration rate (eGFR) was calculated
according to the CKD-EPI (Chronic Kidney Disease Epidemiol-
ogy Collaboration) equation [9]. Other laboratory results that
were registered included haemoglobin level, s-calcium, s-phos-
phate and urinalysis, all were collected at or around the time of
detection of renal failure. Patients were followed until September
30
th 2009, date of starting renal replacement therapy or death,
whichever came first.
Oral sodium phosphate solution (Phosphoral, 45 ml62) was
available without prescription in Iceland during the period March
1999 until May 2009, but since that time it has only been available
by prescription. Yearly sales figures of Phosporal (45 ml62) in
Iceland were obtained from the Icelandic Medicines Control
Agency (personal communication).
All renal biopsies were obtained and processed at Landspitali
University Hospital in Reykjavı ´k. Standard processing of renal
biopsies included light microscopy and immunofluorescence. Light
microscopy biopsies were stained with hematoxylin and eosin,
periodic acid-Schiff, Massons’s trichrome, and Jones methenamine
silver. All cases were examined under polarized light and stained
with von Kossa to differentiate calcium phosphate (nonpolarizable,
von Kossa positive) from calcium oxalate (polarizable, von Kossa
negative). For immunofluorescence, 3 mm cryostat sections
sections were stained with polyclonal FITC-conjugated antibodies
to IgG, IgA, IgM, C3, kappa, lambda, fibrinogen and albuminn
(Dako). Calcium phosphate deposits were quantified on a scale
from 1+ to 4+.
Statistical analysis
Descriptive summary statistics, including mean, median,
standard deviation, and/or range were computed.
Results
Incidence rate
Fifteen cases of acute phosphate nephropathy were diagnosed
between January 2005 and October 2008. They were preceded by
OSPS (Phosphoral) bowel cleansing for colonoscopy in 14 cases
and for preparation for colon operation in one. During this period,
17,651 doses of Phosphoral were sold in the country (incidence
0.085%).
Clinical characteristics of patients
The demographic data and clinical characteristics of the
patients are shown in table 1. Sixty percent of the patients were
women and the mean age at OSPS ingestion was 68.8 years (SD
7.0, range 56–77 years). Thirteen patients had a history of
hypertension and all were treated with either ACE-I or ARB
(N=10) and/or diuretics (N=8) at the time of OSPS bowel
cleansing. One patient had DM type 1 and two patients had DM
type 2. Two patients had a history of colitis ulcerosa. One patient
had no concomitant illness (patient no 11). None of the patients
had known hyperparathyroidism, heart failure or liver disease. At
the presentation of kidney disease, 12 patients had s-calcium and
phosphate levels within normal range, whereas three patients had
low s-calcium and high s-phosphate. The majority of patients
(73%) were anaemic at the time of presentation.
The indication for colonoscopy was anaemia in four cases,
gastrointestinal discomfort (constipation, abdominal pain, diar-
rhea) in three, unknown in four patients and one each had
unexplained weight loss, regular control of colitis ulcerosa (not
active at the time of colonoscopy), control of incidental tumor
finding on CT and preparation for colon operation. It was
documented that all patients had used OSPS for bowel cleansing;
four patients took 45 mL bottles62 and reported having definitely
followed instructions. Patient no 3 threw up the first bottle so she
ingested an extra bottle. Patient no 6 had bowel cleansing three
times with OSPS in a three month period, two times for
colonoscopy and once in preparation for radiography of the
colon. The remaining nine patients all ingested OSPS for bowel
cleansing, but it is not documented whether they followed the
instructions closely or not. Most patients either denied any
symptoms following the OSPS ingestion or symptoms were vague
and non-specific (no symptoms (5), thirst (2), increased diuresis (1),
persistent diarrhea and weight loss (1), malaise (1), cough (1),
unknown (4)). One patient (no 4) had colonoscopy because of
diarrhoea and was diagnosed with Clostridia difficile colitis. This
patient was, unlike the other patients, hospitalized after the
colonoscopy and more acutely ill.
Kidney function
An overview of kidney function before and after ingestion of
OSPS is shown for each patient in table 2. Baseline creatinine was
available in all patients at the average 4.4 months (SD 6.7 range 0–
25.8 months) before the OSPS ingestion. Mean baseline creatinine
was 81.7 mmol/L and mean eGFR was 73.5 ml/min/1.73 m
2.
Four patients had an eGFR of ,60 ml/min/1.73 m
2 at baseline.
Deterioration of kidney function was diagnosed 4.2 months (mean,
SD 4.5, range 1 day–16.3 months) after OSPS ingestion. The
average creatinine at discovery of acute kidney injury was
180.1 mmol/L. The peak creatinine was on average
247.2 mmol/L and 217.8 when the biopsy was performed, which
occurred at a median 6.2 months (range 0.4–39.8 months) after
the ingestion of OSPS. After the initial rise in serum creatinine, it
decreased with time in most patients (87%), but progressed in two,
one of them received treatment for ESRD (no 8) and one died 17.8
months after OSPS ingestion from pneumonia (no 4). Patients
have been followed for an average of 26.6 months after the OSPS
ingestion, ranging from 5.3 to 65.9 months and at latest follow-up,
the average creatinine was 184.3 mmol/L. The average eGFR
declined from 73.5 ml/min/1.73 m
2 at baseline to 37.3 ml/min/
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2 at the end of follow-up and 13 patients had eGFR lower
than 60 ml/min/1.73 m
2.
The most frequent finding in the urinary sediment was sterile
pyuria, with rare red blood cells. In some, hyaline, tubular cell or
granular casts were seen. One patient had a urinary tract infection
at the time of diagnosis. Urine dipstick was negative for protein in
12 patients and trace in one. Two patients had 24-hr urine protein
measured, 260 and 130 mg/day, respectively (Table 1).
Renal biopsy findings
The renal biopsy findings in patients with acute phosphate
nephropathy are shown in Table 3. As could be expected from
this cohort of elderly people, global sclerosis of the glomeruli was
seen in most biopsies (73%). Sampling for light microscopy
included a mean of 20.2 glomeruli (range 5–44), and a mean of
3.7 (18.3%) glomeruli were sclerotic. Other glomeruli appeared
normal. Vascular disease was mild or absent in most patient and
considered to be moderate in one. The typical findings of acute
phosphate nephropathy were present in all patients as shown in
Figure 1. Calcium phosphate deposits were found mostly in distal
tubules and collecting ducts, located within the cytoplasm of
tubular epithelial cells, within tubular lumina, or in the
interstitium. The calcifications did not polarize and stained
intensely with von Kossa stain, which confirmed their composi-
tion as calcium phosphate. The quantity of calcium phosphate
deposits was not associated with time after OSPS ingestion,
increase in creatinine or the final outcome. Tubular injury was
accompanied by interstitial oedema in particular in biopsies of
two patients who had a biopsy taken at the earliest interval from
OSPS ingestion, 12 and 30 days, respectively. Interstitial
inflammation was seen in most biopsies (80%), but there did
not seem to be a relationship between the length of time from
OSPS ingestion to biopsy and the quantity of inflammation.
Chronic, irreversible tubular injury in the form of tubular
atrophy and interstitial fibrosis was seen in all biopsies, ranging
from 10 to 60% of the cortical area sampled.
Discussion
Acute phosphate nephropathy is an iatrogenic cause of kidney
injury after bowel cleansing with OSPS. The relationship between
ingestion of OSPS and the deposition of calcium and phosphate in
the tubules, causing injury with subsequent interstitial scarring
with concomitant loss of kidney function has been documented in
37 cases since 2003 [7]. The majority of the cases (21) come from a
single-center study in the U.S. [2], single cases have been reported
from other U.S. centers [3,10–12], Norway [13], Holland [14],
Belgium [15], UK [16], Lebanon [17], Korea [18], New Zealand
[19], and five from Israel [20], reflecting the widespread use of
OSPS. We have diagnosed 15 additional patients with acute
phosphate nephropathy since 2005, which are described in detail
in this paper. Iceland has a population of 315,000 and one
nephrology referral center which offers a unique opportunity to
estimate the incidence of acute phosphate nephropathy following
OSPS. Comparable estimation has not been possible to do in
other countries [21]. Epidemiological studies, undertaken to assess
the incidence of acute kidney injury after OSPS, have yielded
conflicting results and have not fully elucidated this issue [22]. The
largest study comprised 9799 individuals, 50 years of age or older,
who had received either OSPS or polyethylene glycol (PEG) for
bowel cleansing for colonoscopy. The incidence of acute kidney
injury, defined by a $50% increase in serum creatinine, was
1.29% and 0.92%, for OSPS and PEG, respectively [23]. These
studies are all hampered by the lack of renal biopsies for the
diagnosis of acute phosphate nephropathy.
In total, 17,651 doses of Phosphoral (45 ml62) were sold in
Iceland during the study period. The incidence of acute
phosphate nephropathy is thus 1/1177 doses of OSPS or
Table 1. Demographics and clinical characteristics of patients with acute phosphate nephropathy after OSPS ingestion.
a
Patient Age, sex HT DM ACE-i/ARB Diuretics Proteinuria Urinary sediment S- calcium S-phosphorus Hemoglobin
1 59F Y N Y Y Negative 10–25 wbc, 2–5 rbc 2.38 1.43 108
2 58M Y N Y Y 260 mg/24 hr No abnormalities 2.25 1.17 109
3 75F Y N Y Y 0.13 g/24 hr No abnormalities 1.05
b 1.86 112
4 65M N Y type 1 N N Negative 2–5 wbc, 1–2 rbc
c 1.97 1.66 126
5 71F Y N Y N Negative 5–10 wbc, 1–2 rbc 1.32 1.19 84
6 74F Y N Y N Negative .100 wbc, 1–2 rbc, +++bacteria
d 1.23 1.60 131
7 69F Y N Y N Negative 5–10 wbc, 1–2 rbc 2.20 1.33 114
8 77M Y Y type 2 N Y Negative No abnormalities 1.0
b 2.31 111
9 56M Y N Y Y Negative No abnormalities 2.26 1.12 118
10 74F Y N N Y Negative 10–25 wbc, 1–2 rbc 1.21
b 1.33 114
11 62F N N N N Negative No abnormalities 1.30 1.02 150
12 71M Y Y type 2 Y N (+) 2–5 wbc, 5–10 rbc
c 1.13
b 0.99 135
13 71M Y N Y N Negative 1–2 wbc 1.23
b 1.41 116
14 75F Y N N Y Negative 1–2 wbc, 2–5 rbc
c 1.23
b 1.21 85
15 75F Y N Y Y Negative 25–50 wbc 1.25
b 1.39 105
aAbbreviation used in table: HT, hypertension; DM, diabetes mellitus; ACE-i, Angiotensin convertive enzyme inhibitor; ARB, angiotensin receptor blockade; Y, yes; N, no;
WNR, withing normal range; wbc, white blood cells; rbc, red blood cells. Normal values for s-calcium, 2.15–2.60 mmol/L; ionized calcium, 1.13–1.33 mmol/L; s-
phosphorus, 0.75–1.65 mmol/L; Hemoglobin, 118–152 g/L (women), 134–171 g/L (men).
bIonized s-calcium.
cIn these sediments, hyaline, tubular cell, granular or Muddy Brown casts were also seen.
dAfter treatment of the UTI, urine analysis was normal.
doi:10.1371/journal.pone.0013484.t001
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taken into account (30,958). However, these numbers likely
underestimate the magnitude of the problem, as sold doses of
OSPS have not necessarily all been ingested and also because the
diagnosis requires a kidney biopsy. Our study shows that the
symptoms are frequently vague or even absent, and that the
diagnosis of acute kidney injury is commonly found by chance.
When these patients present with a rise in creatinine they are
unlikely to undergo a renal biopsy for definite diagnosis for
several reasons: Individuals at risk for developing acute phosphate
nephropathy are elderly people (all above 55 years in our study),
have a history of hypertension and are treated with medications
that can cause fluctuations in the kidney function, i.e. diuretics
and ACE-I or ARB and present with a bland urine sediment
without clinically important proteinuria. The lag time between
the marketing of the OSPS and the recognition of acute
phosphate nephropathy as a side effect, which was six years in
our country and up to 13 years in the U.S., emphasizes how
latent and unexpected this condition is.
How do our results then compare with findings in other
populations? Twenty-five cases of acute phosphate nephropathy
have been reported in the medical literature coming from the U.S.
[2,3,10–12]. However, based on our data we would expect 15,000
cases, in light of the proportional size differences of the U.S. and
Icelandic populations (the U.S. has approximately thousand fold
more inhabitants than Iceland). This striking difference is an
obvious argument for the underreporting of acute phosphate
nephropathy worldwide. Furthermore, we predict that the
prevalence of acute phosphate nephropathy is even greater in
the U.S., and the direct extrapolation based on number of
inhabitants may be a bias towards an underestimation of the
problem. OSPS has been the preferred purgative in both
countries; one U.S. center reported sodium phosphate purgatives
to be used in up to 80–90% of patients for bowel preparation for
colonoscopy [6]. It is, however, likely that colonoscopies are done
more frequently in the U.S. compared to Iceland as routine
screening for colon and rectal cancer with colonoscopy has not
been put into practice in Iceland. In the U.S. the rate of screening
colonoscopy increased dramatically after the introduction of full
Medicare coverage of the procedure in 2002 [24,25].
The main limitation of the present study is its retrospective
character and the lack of a control group. Our calculation of the
national incidence of acute phosphate nephropathy is therefore
crude, and most likely biased towards underestimation of the
problem. Also there is incomplete information on the adherence to
the prescribed hydration regimens and limited ability to find new
risk factors. Despite these limitations, this is the only study
available that is able to estimate the magnitude of the renal
complication of OSPS use.
The large number of cases that have been diagnosed in Iceland
compared to other countries is most likely due to the close
collaboration of a small group of nephrologists (7) who receive all
nephrology referrals in the country. They have been aware of
acute phosphate nephropathy as a complication of OSPS use from
the beginning of 2005. The nephrologists attend the meetings with
a single pathologist and discuss all cases. Such setup can increase
the awareness of both sides and may have lead to an increase in
biopsies taken, especially when there was a history of exposure of
OSPS (which has become a routine question in the case of an
unexplained rise in s-creatinine). The pathologist may also have
Table 2. Changes in kidney function before and after ingestion of oral sodium phosphate solutions.
a
Patient Age, sex Kidney function -1
b Time -1
f Kidney function 1
c Time 1
g Kidney function 2
d Time 2
h Kidney function 3
e Time 3
i
SCr eGFR Days SCr Days SCr Months SCr eGFR Months
1 59F 48 103 22 105 288 105 11.7 80 70 20.5
2 58M 67 101 93 170 95 166 9.6 116 59 22.9
3 75F 54 89 253 255 1 380 0.4 173 25 39.2
4 65M 73 93 61 120 0 312 1.0 440 11 17.8
5 71F 62 87 199 153 52 138 4.3 112 43 16.9
6 74F 66 79 10 310 104 308 3.5 121 38 7.7
7 69F 68 79 58 160 146 115 15.1 134 35 33.6
8 77M 92 69 7 131 2 555 39.8 554 8 46.4
9 56M 103 70 92 164 31 125 4.2 114 62 5.3
10 74F 81 62 775 194 45 198 6.2 170 25 27.2
11 62F 88 61 28 127 489 105 22.2 101 51 36
12 71M 110 58 3 144 275 132 18.3 144 41 33.8
13 71M 115 55 315 280 101 290 4.1 208 26 43.1
14 75F 98 49 0 239 185 221 6.6 194 21 23.1
15 75F 100 48 61 150 62 117 3.8 103 45 25.8
aAbbreviations used in table: SCr, s-creatinine in mmol/L; eGFR, estimated glomerular filtration rate in ml/min/1.73 m
2, calculated using CKD-EPI (Chronic Kidney Disease
Epidemiology Collaboration) equation (see Methods).
bKidney function -1, baseline value of SCr and eGFR (before ingestion of OSPS);
cKidney function 1, SCr at presentation;
dKidney function 2, SCr at the time of renal biopsy;
eKidney function 3, SCr and eGFR at the time of last follow-up.
fTime -1, days between measurement of baseline creatinine and the ingestion of OSPS;
gTime 1, days between the ingestion of OSPS and the discovery of AKI;
hTime 2, months between the ingestion of OSPS and kidney biopsy;
iTime 3, months between ingestion of OSPS and the last follow-up.
doi:10.1371/journal.pone.0013484.t002
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OSPS use, although the diagnosis is rather straightforward and
requires abundant tubular deposits of calcium phosphate
(Figure 1). Alternatively, the Icelandic population may be more
prone to develop acute phosphate nephropathy due to unknown
genetic and environmental factors, but remarkable similarities
between our patient group and the previously reported cases
argues against that. The majority of our cases were women (60%)
with an average age of 68.8 years and all patients were older than
55 years. This is comparable to the cases that have been diagnosed
worldwide, 81% is female and their mean age was 66.1, ranging
from 39–85 years and 70% older than 60 years [2,3,10–20]. The
co-morbidities in our patients were also similar to the other cases,
87% of our patients had hypertension and all used either diuretics,
and/or ACE-I or ARB, 20% had diabetes and 27% had e-GFR
,60 ml/min per 1.73 m
2 at baseline. These risk factors have been
reported with a similar rate before, 81% of previously reported
cases have hypertension and most have been treated with the
aforementioned drugs, 14% have diabetes and 22% have baseline
e-GFR ,60 ml/min per 1.73 m
2 [7]. In addition to this,
inappropriate use of OSPS could be responsible for the high rate
of cases in our country. The use of OSPS can be criticized in two
of the patients, one who was exposed to repeated doses in a short
period of time, and another who turned out to have an active
colitis. We included all cases in this study, as clinical practice is
clearly not always according to recommendations.
Table 3. Biopsy results of 15 patients after ingestion of oral sodium phosphate solution.
a
Patient Glomeruli Interstitium Arteriolar hyalinosis Other pathology
Total number Global sclerosis Ca/P TA/IF Oedema Inflammation
13 2 2 4 + 50% - ++ none/mild No
22 9 2 3 + 40% - 6 none/mild No
35 0 3 + 30% ++ - none/mild No
42 0 0 2 + 30% ++ + mild No
52 4 4 3 + 30% - + none/mild No
62 2 5 3 + 30% ++ none/mild No
72 2 9 2 + 40% - + mild No
81 9 3 2 + 60% - 6 moderate No
92 2 5 2 + 40% - 6 mild No
10 10 0 3+ 30% - 6 none/mild No
11 11 3 3+ 10% - - none/mild No
12 10 4 1+ 30% ++ mild No
13 8 0 3+ 50% (+) - none/mild No
14 25 5 3+ 30% - + mild No
15 44 14 3+ 50% - ++ mild No
aAbbreviations used in table: Ca, calcium; P, phosphate; TA, tubular atrophy; IF, interstitial fibrosis.
doi:10.1371/journal.pone.0013484.t003
Figure 1. Renal biopsy findings in acute phosphate nephropathy. A) Abundant calcifications are seen within tubules and in the interstitium.
Adjacent tubules are athrophic and there is interstitial fibrosis (Hematoxylin and eosin staining, original magnification x 400). B) Positive von Kossa
staining in the same biopsy confirms that the calcifications are composed of calcium phosphate (original magnification x 400).
doi:10.1371/journal.pone.0013484.g001
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OSPS on kidney function and future health of these patients is of
major concern. Although the kidney function improved in most
patients with time, one patient reached end-stage renal disease and
one died with a pre-end-stage renal failure. At the end of follow-
up, the eGFR had decreased by an average of 36 ml/min/
1.73 m
2 from the baseline value. Studies have shown that acute
kidney injury and chronic kidney disease are associated with an
increased risk of cardiovascular disease and mortality [26–28].
This study is an important addition to the reported cases of
acute phosphate nephropathy and confirms the risk factors that
have been suggested in other studies. We were able to reveal the
incidence of this complication due to the unique setting in our
country. Approximately one out of every thousand sold doses of
OSPS resulted in acute kidney injury and follow-up showed that
the long-term consequences were not benign. This information
can be used in other populations to estimate the impact of OSPS
use. Our results suggest that acute phosphate nephropathy
following OSPS is underestimated worldwide and that it may be
an important iatrogenic cause of chronic kidney disease in the
elderly now and in the near future.
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